menu
    • menu

    Company profile for Iovance Biotherapeutics

    NEW Drugs in Dev: 9
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was initially developed by Dr. Steven A. Rosenberg at the National Cancer Institute (NCI). In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology were reported by NCI to have...
    Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was initially developed by Dr. Steven A. Rosenberg at the National Cancer Institute (NCI). In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology were reported by NCI to have achieved objective and complete response criteria, respectively. Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrate

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Iovance BiotherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    999 Skyway Road Suite 150 San Carlos, CA 94070
    Telephone
    Telephone
    650-260-7120
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.iovance.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BePharma

    Not Confirmed

    envelop Contact Supplier

    BePharma

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Iovance Showcases Strong Q4 and Full-Year 2025 Results
    Iovance Showcases Strong Q4 and Full-Year 2025 Results

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3243360/0/en/Iovance-Biotherapeutics-Highlights-Strong-Fourth-Quarter-and-Full-Year-2025-Results-Business-Achievements-and-Corporate-Updates.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    Iovance Biotherapeutics To Release Q4 2025 Financial Results
    Iovance Biotherapeutics To Release Q4 2025 Financial Results

    11 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/11/3236648/0/en/Iovance-Biotherapeutics-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Corporate-Updates-on-Tuesday-February-24-2026.html

    GLOBENEWSWIRE
    11 Feb 2026
    Share Share
    Real-World Data Backs Early Amtagvi Use For Advanced Melanoma
    Real-World Data Backs Early Amtagvi Use For Advanced Melanoma

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3233518/0/en/Best-in-Class-Real-World-Data-Support-Early-Amtagvi-Treatment-in-Advanced-Melanoma.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Iovance Grants Inducements Under Nasdaq Rules LR 5635(C)(4)
    Iovance Grants Inducements Under Nasdaq Rules LR 5635(C)(4)

    16 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/16/3220580/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    16 Jan 2026
    Share Share
    Iovance Biotherapeutics Discloses Inducement Grants Per Nasdaq
    Iovance Biotherapeutics Discloses Inducement Grants Per Nasdaq

    19 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/19/3208770/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    19 Dec 2025
    Share Share
    Iovance Biotherapeutics Discloses Inducement Grants Per NASDAQ
    Iovance Biotherapeutics Discloses Inducement Grants Per NASDAQ

    21 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/21/3193043/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    21 Nov 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search